FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited

Gynecologic Oncology

Volumn 142, Issue 3, 2016, Pages 597-607

  Ataseven, Beyhan ^a   Chiva, Luis M ^b   Harter, Philipp ^a   Gonzalez Martin, Antonio ^b   du Bois, Andreas ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

^b MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Diagnosis; FIGO stage IV; Ovarian cancer; Prognosis; Therapy

Indexed keywords

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; FALLOPIAN TUBE CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; REVIEW; NEOPLASM; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; UTERINE TUBE TUMOR;

FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84975045658     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.06.013     Document Type: Review

References (88)

1. [1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2015), 87–108.
2. [2] Heintz, A.P., Odicino, F., Maisonneuve, P., Quinn, M.A., Benedet, J.L., Creasman, W.T., Ngan, H.Y., Pecorelli, S., Beller, U., Carcinoma of the fallopian tube. FIGO 26th annual report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 95:Suppl. 1 (2006), S145–S160.
3. [3] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2015. CA Cancer J. Clin. 65 (2015), 5–29.
4. [4] Heintz, A.P., Odicino, F., Maisonneuve, P., Quinn, M.A., Benedet, J.L., Creasman, W.T., Ngan, H.Y., Pecorelli, S., Beller, U., Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 95:Suppl. 1 (2006), S161–S192.
5. [5] Ataseven, B., Grimm, C., Harter, P., Heitz, F., Traut, A., Prader, S., du Bois, A., Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecol. Oncol., 2015.
6. [6] Bonnefoi, H., A'Hern, R.P., Fisher, C., Macfarlane, V., Barton, D., Blake, P., Shepherd, J.H., Gore, M.E., Natural history of stage IV epithelial ovarian cancer. J. Clin. Oncol. 17 (1999), 767–775.
7. [7] Aletti, G.D., Dowdy, S.C., Podratz, K.C., Cliby, W.A., Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol. Oncol. 105 (2007), 84–89.
8. [8] Akahira, J.I., Yoshikawa, H., Shimizu, Y., Tsunematsu, R., Hirakawa, T., Kuramoto, H., Shiromizu, K., Kuzuya, K., Kamura, T., Kikuchi, Y., Kodama, S., Yamamoto, K., Sato, S., Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol. Oncol. 81 (2001), 398–403.
9. [9] Winter, W.E. 3rd, Maxwell, G.L., Tian, C., Sundborg, M.J., Rose, G.S., Rose, P.G., Rubin, S.C., Muggia, F., McGuire, W.P., Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 26 (2008), 83–89.
10. [10] Ogawa, K., Yoshii, Y., Aoki, Y., Nagai, Y., Tsuchida, Y., Toita, T., Kakinohana, Y., Tamaki, W., Iraha, S., Adachi, G., Hirakawa, M., Kamiyama, K., Inamine, M., Hyodo, A., Murayama, S., Treatment and prognosis of brain metastases from gynecological cancers. Neurol. Med. Chir. (Tokyo) 48 (2008), 57–62 (discussion 62-3).
11. [11] Cormio, G., Rossi, C., Cazzolla, A., Resta, L., Loverro, G., Greco, P., Selvaggi, L., Distant metastases in ovarian carcinoma. Int. J. Gynecol. Cancer 13 (2003), 125–129.
12. [12] Dauplat, J., Hacker, N.F., Nieberg, R.K., Berek, J.S., Rose, T.P., Sagae, S., Distant metastases in epithelial ovarian carcinoma. Cancer 60 (1987), 1561–1566.
13. [13] Serov, S., Scully, R., Sobin, L., Histological Typing of Ovarian Tumors. 1973, World Health Organiszation (International Histological Classification of Tumours, No 9).
14. [14] Kottmeier, H.L., Presentation of therapeutic results in carcinoma of the female pelvis: experience of the annual report on the results of treatment in carcinoma of the uterus, vagina, and ovary. Gynecol. Oncol. 4 (1976), 13–19.
15. [15] Prat, J., Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 124 (2014), 1–5.
16. [16] Rosendahl, M., Hogdall, C.K., Mosgaard, B.J., Restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian, fallopian tube, and primary peritoneal cancer. Int. J. Gynecol. Cancer, 2016.
17. [17] Paik, E.S., Lee, Y.Y., Lee, E.J., Choi, C.H., Kim, T.J., Lee, J.W., Bae, D.S., Kim, B.G., Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. Obstet Gynecol Sci 58 (2015), 124–134.
18. [18] Zaren, H.A., Copeland, E.M. 3rd., Inguinal node metastases. Cancer 41 (1978), 919–923.
19. [19] Musumeci, R., Banfi, A., Bolis, G., Candiani, G.B., De Palo, G., Di Re, F., Lucina, L., Lattuada, A., Mangioni, C., Mattioli, G., Natale, N., Lymphangiography in patients with ovarian epithelial cancer: an evaluation of 289 consecutive cases. Cancer 40 (1977), 1444–1449.
20. [20] Heitz, F., Ognjenovic, D., Harter, P., Kommoss, S., Ewald-Riegler, N., Haberstroh, M., Gomez, R., Barinoff, J., Traut, A., du Bois, A., Abdominal wall metastases in patients with ovarian cancer after laparoscopic surgery: incidence, risk factors, and complications. Int. J. Gynecol. Cancer 20 (2010), 41–46.
21. [21] Ataseven, B., du Bois, A., Harter, P., Prader, S., Grimm, C., Kurzeder, C., Schneider, S., Heikaus, S., Kahl, A., Traut, A., Heitz, F., Impact of abdominal wall metastases on prognosis in ovarian cancer. Int. J. Gynecol. Cancer, 2016 (in press).
22. [22] Heintz, A.P., Odicino, F., Maisonneuve, P., Beller, U., Benedet, J.L., Creasman, W.T., Ngan, H.Y., Sideri, M., Pecorelli, S., Carcinoma of the ovary. J Epidemiol Biostat 6 (2001), 107–138.
23. [23] http://www.seer.com, 2014.
24. [24] Chiva, L., Lapuente, F., Castellanos, T., Alonso, S., Gonzalez-Martin, A., What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer?. Ann. Surg. Oncol., 2015.
25. [25] Dvoretsky, P.M., Richards, K.A., Angel, C., Rabinowitz, L., Stoler, M.H., Beecham, J.B., Bonfiglio, T.A., Distribution of disease at autopsy in 100 women with ovarian cancer. Hum. Pathol. 19 (1988), 57–63.
26. [26] Raban, O., Peled, Y., Krissi, H., Goldberg, N., Aviram, A., Sabah, G., Levavi, H., Eitan, R., The significance of paracardiac lymph-node enlargement in patients with newly diagnosed stage IIIC ovarian cancer. Gynecol. Oncol. 138 (2015), 259–262.
27. [27] Prader, S., Harter, P., Grimm, C., Traut, A., Waltering, K.U., Alesina, P.F., Heikaus, S., Ataseven, B., Heitz, F., Schneider, S., du Bois, A., Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. Gynecol. Oncol., 2016.
28. [28] Di Guilmi, J., Salvo, G., Mehran, R., Sood, A.K., Coleman, R.L., Lu, K.H., Vaporciyan, A., Ramirez, P.T., Role of video-assisted thoracoscopy in advanced ovarian cancer: a literature review. Int. J. Gynecol. Cancer, 2016.
29. [29] Risum, S., Hogdall, C., Loft, A., Berthelsen, A.K., Hogdall, E., Nedergaard, L., Lundvall, L., Engelholm, S.A., Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?. Gynecol. Oncol. 116 (2010), 395–398.
30. [30] Fruscio, R., Sina, F., Dolci, C., Signorelli, M., Crivellaro, C., Dell'Anna, T., Cuzzocrea, M., Guerra, L., Milani, R., Messa, C., Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer. Gynecol. Oncol. 131 (2013), 689–693.
31. [31] Hynninen, J., Auranen, A., Carpen, O., Dean, K., Seppanen, M., Kemppainen, J., Lavonius, M., Lisinen, I., Virtanen, J., Grenman, S., FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol. Oncol. 126 (2012), 64–68.
32. [32] Kobayashi, H., Yamada, Y., Sado, T., Sakata, M., Yoshida, S., Kawaguchi, R., Kanayama, S., Shigetomi, H., Haruta, S., Tsuji, Y., Ueda, S., Kitanaka, T., A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int. J. Gynecol. Cancer 18 (2008), 414–420.
33. [33] Buys, S.S., Partridge, E., Black, A., Johnson, C.C., Lamerato, L., Isaacs, C., Reding, D.J., Greenlee, R.T., Yokochi, L.A., Kessel, B., Crawford, E.D., Church, T.R., Andriole, G.L., Weissfeld, J.L., Fouad, M.N., Chia, D., O'Brien, B., Ragard, L.R., Clapp, J.D., Rathmell, J.M., Riley, T.L., Hartge, P., Pinsky, P.F., Zhu, C.S., Izmirlian, G., Kramer, B.S., Miller, A.B., Xu, J.L., Prorok, P.C., Gohagan, J.K., Berg, C.D., Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305 (2011), 2295–2303.
34. [34] Jacobs, I.J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J.K., Amso, N.N., Apostolidou, S., Benjamin, E., Cruickshank, D., Crump, D.N., Davies, S.K., Dawnay, A., Dobbs, S., Fletcher, G., Ford, J., Godfrey, K., Gunu, R., Habib, M., Hallett, R., Herod, J., Jenkins, H., Karpinskyj, C., Leeson, S., Lewis, S.J., Liston, W.R., Lopes, A., Mould, T., Murdoch, J., Oram, D., Rabideau, D.J., Reynolds, K., Scott, I., Seif, M.W., Sharma, A., Singh, N., Taylor, J., Warburton, F., Widschwendter, M., Williamson, K., Woolas, R., Fallowfield, L., McGuire, A.J., Campbell, S., Parmar, M., Skates, S.J., Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387 (2016), 945–956.
35. [35] Konecny, G.E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K.R., Dering, J., Ginther, C., Chen, H.W., Dowdy, S., Cliby, W., Gostout, B., Podratz, K.C., Keeney, G., Wang, H.J., Hartmann, L.C., Slamon, D.J., Goode, E.L., Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J. Natl. Cancer Inst., 106, 2014.
36. [36] Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., Johnson, D.S., Trivett, M.K., Etemadmoghadam, D., Locandro, B., Traficante, N., Fereday, S., Hung, J.A., Chiew, Y.E., Haviv, I., Gertig, D., DeFazio, A., Bowtell, D.D., Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14 (2008), 5198–5208.
37. [37] Integrated genomic analyses of ovarian carcinoma. Nature, 474, 2011, 609–615.
38. [38] Zhang, G.N., Liu, H., Huang, J.M., Wang, L., Zhao, J.S., Li, C., Mi, K., Zhu, Y., Cheng, J., Zha, X., TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer. Gynecol. Oncol. 132 (2014), 752–757.
39. [39] Riester, M., Wei, W., Waldron, L., Culhane, A.C., Trippa, L., Oliva, E., Kim, S.H., Michor, F., Huttenhower, C., Parmigiani, G., Birrer, M.J., Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J. Natl. Cancer Inst., 106, 2014.
40. [40] Tucker, S.L., Gharpure, K., Herbrich, S.M., Unruh, A.K., Nick, A.M., Crane, E.K., Coleman, R.L., Guenthoer, J., Dalton, H.J., Wu, S.Y., Rupaimoole, R., Lopez-Berestein, G., Ozpolat, B., Ivan, C., Hu, W., Baggerly, K.A., Sood, A.K., Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer. Clin. Cancer Res. 20 (2014), 3280–3288.
41. [41] Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M.J., Webb, P.M., Stewart, C., Friedlander, M., Fox, S., Bowtell, D., Mitchell, G., BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 30 (2012), 2654–2663.
42. [42] Hennessy, B.T., Timms, K.M., Carey, M.S., Gutin, A., Meyer, L.A., Flake, D.D. 2nd, Abkevich, V., Potter, J., Pruss, D., Glenn, P., Li, Y., Li, J., Gonzalez-Angulo, A.M., McCune, K.S., Markman, M., Broaddus, R.R., Lanchbury, J.S., Lu, K.H., Mills, G.B., Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol. 28 (2010), 3570–3576.
43. [43] Pennington, K.P., Walsh, T., Harrell, M.I., Lee, M.K., Pennil, C.C., Rendi, M.H., Thornton, A., Norquist, B.M., Casadei, S., Nord, A.S., Agnew, K.J., Pritchard, C.C., Scroggins, S., Garcia, R.L., King, M.C., Swisher, E.M., Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20 (2014), 764–775.
44. [44] du Bois, A., Reuss, A., Pujade-Lauraine, E., Harter, P., Ray-Coquard, I., Pfisterer, J., Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115 (2009), 1234–1244.
45. [45] Harter, P., Johnson, T., Berton-Rigaud, D., Park, S.Y., Friedlander, M., Del Campo, J.M., Shimada, M., Forget, F., Mirza, M.R., Colombo, N., Zamagni, C., Chan, J.K., Imhof, M., Herzog, T.J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C.F., du Bois, A., BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol. Oncol. 140 (2016), 443–449.
46. [46] Mizuno, M., Kajiyama, H., Shibata, K., Mizuno, K., Kawai, M., Nagasaka, T., Kikkawa, F., Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients. Br. J. Cancer 112 (2015), 1376–1383.
47. [47] Hyman, D.M., Long, K.C., Tanner, E.J., Grisham, R.N., Arnold, A.G., Bhatia, J., Phillips, M.F., Spriggs, D.R., Soslow, R.A., Kauff, N.D., Levine, D.A., Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol. Oncol. 126 (2012), 224–228.
48. [48] Bristow, R.E., Montz, F.J., Lagasse, L.D., Leuchter, R.S., Karlan, B.Y., Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol. Oncol. 72 (1999), 278–287.
49. [49] Ataseven, B., Harter, P., Grimm, C., Heitz, F., Heikaus, S., Traut, A., Kahl, A., Kurzeder, C., Prader, S., du Bois, A., The revised 2014 FIGO staging system for epithelial ovarian cancer: is a subclassification into FIGO stage IVA and IVB justified?. Gynecol. Oncol., 2016 (in press).
50. [50] Mackay, H.J., Brady, M.F., Oza, A.M., Reuss, A., Pujade-Lauraine, E., Swart, A.M., Siddiqui, N., Colombo, N., Bookman, M.A., Pfisterer, J., du Bois, A., Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int. J. Gynecol. Cancer 20 (2010), 945–952.
51. [51] Trope, C.G., Elstrand, M.B., Sandstad, B., Davidson, B., Oksefjell, H., Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?. Eur. J. Cancer 48 (2012), 2146–2154.
52. [52] Wimberger, P., Wehling, M., Lehmann, N., Kimmig, R., Schmalfeldt, B., Burges, A., Harter, P., Pfisterer, J., du Bois, A., Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann. Surg. Oncol. 17 (2010), 1642–1648.
53. [53] Bristow, R.E., Tomacruz, R.S., Armstrong, D.K., Trimble, E.L., Montz, F.J., Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002), 1248–1259.
54. [54] Hoskins, W.J., Bundy, B.N., Thigpen, J.T., Omura, G.A., The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 47 (1992), 159–166.
55. [55] Chang, S.J., Hodeib, M., Chang, J., Bristow, R.E., Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol. Oncol. 130 (2013), 493–498.
56. [56] Bookman, M.A., Brady, M.F., McGuire, W.P., Harper, P.G., Alberts, D.S., Friedlander, M., Colombo, N., Fowler, J.M., Argenta, P.A., De Geest, K., Mutch, D.G., Burger, R.A., Swart, A.M., Trimble, E.L., Accario-Winslow, C., Roth, L.M., Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup. J. Clin. Oncol. 27 (2009), 1419–1425.
57. [57] Curtin, J.P., Malik, R., Venkatraman, E.S., Barakat, R.R., Hoskins, W.J., Stage IV ovarian cancer: impact of surgical debulking. Gynecol. Oncol. 64 (1997), 9–12.
58. [58] Rauh-Hain, J.A., Rodriguez, N., Growdon, W.B., Goodman, A.K., Boruta, D.M. 2nd, Horowitz, N.S., del Carmen, M.G., Schorge, J.O., Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann. Surg. Oncol. 19 (2012), 959–965.
59. [59] Chi, D.S., Franklin, C.C., Levine, D.A., Akselrod, F., Sabbatini, P., Jarnagin, W.R., DeMatteo, R., Poynor, E.A., Abu-Rustum, N.R., Barakat, R.R., Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94 (2004), 650–654.
60. [60] Harter, P., Muallem, Z.M., Buhrmann, C., Lorenz, D., Kaub, C., Hils, R., Kommoss, S., Heitz, F., Traut, A., du Bois, A., Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol. Oncol. 121 (2011), 615–619.
61. [61] Janco JMT, Glaser G, Kim B, McGree ME, Weaver AL, Cliby WA, Dowdy SC, Bakkum-Gamez JN. Development of a prediction model for residual disease in newly diagnosed advanced ovarian cancer. Gynecol. Oncol.
62. [62] Liu, Z., Beach, J.A., Agadjanian, H., Jia, D., Aspuria, P.J., Karlan, B.Y., Orsulic, S., Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol. Oncol. 139 (2015), 394–400.
63. [63] Petrillo, M., Vizzielli, G., Fanfani, F., Gallotta, V., Cosentino, F., Chiantera, V., Legge, F., Carbone, V., Scambia, G., Fagotti, A., Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept. Gynecol. Oncol. 139 (2015), 5–9.
64. [64] Fagotti, A., Fanfani, F., Ludovisi, M., Lo Voi, R., Bifulco, G., Testa, A.C., Scambia, G., Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol. Oncol. 96 (2005), 729–735.
65. [65] Kehoe, S., Hook, J., Nankivell, M., Jayson, G.C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., Dobbs, S., Essapen, S., Twigg, J., Herod, J., McCluggage, G., Parmar, M., Swart, A.M., Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386 (2015), 249–257.
66. [66] Vergote, I., Trope, C.G., Amant, F., Kristensen, G.B., Ehlen, T., Johnson, N., Verheijen, R.H., van der Burg, M.E., Lacave, A.J., Panici, P.B., Kenter, G.G., Casado, A., Mendiola, C., Coens, C., Verleye, L., Stuart, G.C., Pecorelli, S., Reed, N.S., Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363 (2010), 943–953.
67. [67] du Bois, A., Harter, P., Understanding and Optimizing the Potential Role of Surgical Debulking in Advanced Epithelial Ovarian Cancer. 2010, American Society of Clinical Oncology, e13–e17 (ASCO educational book).
68. [68] Eitan, R., Krissi, H., Levavi, H., Sabah, G., Peled, Y., Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention. PLoS One, 8, 2013, e55645.
69. [69] Neijt, J.P., Engelholm, S.A., Tuxen, M.K., Sorensen, P.G., Hansen, M., Sessa, C., de Swart, C.A., Hirsch, F.R., Lund, B., van Houwelingen, H.C., Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18 (2000), 3084–3092.
70. [70] Ozols, R.F., Bundy, B.N., Greer, B.E., Fowler, J.M., Clarke-Pearson, D., Burger, R.A., Mannel, R.S., DeGeest, K., Hartenbach, E.M., Baergen, R., Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003), 3194–3200.
71. [71] du Bois, A., Luck, H.J., Meier, W., Adams, H.P., Mobus, V., Costa, S., Bauknecht, T., Richter, B., Warm, M., Schroder, W., Olbricht, S., Nitz, U., Jackisch, C., Emons, G., Wagner, U., Kuhn, W., Pfisterer, J., A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003), 1320–1329.
72. [72] du Bois, A., Quinn, M., Thigpen, T., Vermorken, J., Avall-Lundqvist, E., Bookman, M., Bowtell, D., Brady, M., Casado, A., Cervantes, A., Eisenhauer, E., Friedlaender, M., Fujiwara, K., Grenman, S., Guastalla, J.P., Harper, P., Hogberg, T., Kaye, S., Kitchener, H., Kristensen, G., Mannel, R., Meier, W., Miller, B., Neijt, J.P., Oza, A., Ozols, R., Parmar, M., Pecorelli, S., Pfisterer, J., Poveda, A., Provencher, D., Pujade-Lauraine, E., Randall, M., Rochon, J., Rustin, G., Sagae, S., Stehman, F., Stuart, G., Trimble, E., Vasey, P., Vergote, I., Verheijen, R., Wagner, U., 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 16:Suppl. 8 (2005), viii7–viii12.
73. [73] Vasey, P.A., Jayson, G.C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S.B., Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 96 (2004), 1682–1691.
74. [74] du Bois, A., Herrstedt, J., Hardy-Bessard, A.C., Muller, H.H., Harter, P., Kristensen, G., Joly, F., Huober, J., Avall-Lundqvist, E., Weber, B., Kurzeder, C., Jelic, S., Pujade-Lauraine, E., Burges, A., Pfisterer, J., Gropp, M., Staehle, A., Wimberger, P., Jackisch, C., Sehouli, J., Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J. Clin. Oncol. 28 (2010), 4162–4169.
75. [75] Pfisterer, J., Weber, B., Reuss, A., Kimmig, R., du Bois, A., Wagner, U., Bourgeois, H., Meier, W., Costa, S., Blohmer, J.U., Lortholary, A., Olbricht, S., Stahle, A., Jackisch, C., Hardy-Bessard, A.C., Mobus, V., Quaas, J., Richter, B., Schroder, W., Geay, J.F., Luck, H.J., Kuhn, W., Meden, H., Nitz, U., Pujade-Lauraine, E., Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J. Natl. Cancer Inst. 98 (2006), 1036–1045.
76. [76] Chan, J.K., Brady, M.F., Penson, R.T., Huang, H., Birrer, M.J., Walker, J.L., DiSilvestro, P.A., Rubin, S.C., Martin, L.P., Davidson, S.A., Huh, W.K., O'Malley, D.M., Boente, M.P., Michael, H., Monk, B.J., Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N. Engl. J. Med. 374 (2016), 738–748.
77. [77] Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P.B., Cormio, G., Sorio, R., Cavazzini, M.G., Ferrandina, G., Breda, E., Murgia, V., Sacco, C., Cinieri, S., Salutari, V., Ricci, C., Pisano, C., Greggi, S., Lauria, R., Lorusso, D., Marchetti, C., Selvaggi, L., Signoriello, S., MC, P., Di Maio, M., Perrone, F., Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 15 (2014), 396–405.
78. [78] Perren, T.J., Swart, A.M., Pfisterer, J., Ledermann, J.A., Pujade-Lauraine, E., Kristensen, G., Carey, M.S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stahle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M.R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M.K., Oza, A.M., A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365 (2011), 2484–2496.
79. [79] Burger, R.A., Brady, M.F., Bookman, M.A., Fleming, G.F., Monk, B.J., Huang, H., Mannel, R.S., Homesley, H.D., Fowler, J., Greer, B.E., Boente, M., Birrer, M.J., Liang, S.X., Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365 (2011), 2473–2483.
80. [80] L. Randall, R. Burger, H. Nguyen, G. Kong, M. Bookman, G. Fleming, B. Monk, R. Mannel, Birrer, M. Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab. Gynecol. Oncol.2013;130: e33-e34.
81. [81] du Bois, A., Floquet, A., Kim, J.W., Rau, J., del Campo, J.M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., Mirza, M.R., Monk, B.J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K.H., Mouret-Reynier, M.A., Kim, J.H., Kurzeder, C., Lesoin, A., Vasey, P., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B.G., Herzog, T.J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R., Harter, P., Incorporation of pazopanib in maintenance therapy of ovarian cancer. J. Clin. Oncol. 32 (2014), 3374–3382.
82. [82] du Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., Del Campo, J.M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidzinski, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M.R., Scambia, G., Meier, W., Nicoletto, M.O., Bjorge, L., Lortholary, A., Sailer, M.O., Merger, M., Harter, P., Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 17 (2016), 78–89.
83. [83] NCCN, NCCN Guideline Version 2.2015 Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Pertoneal Cancer. 2015.
84. [84] Salani, R., Backes, F.J., Fung, M.F., Holschneider, C.H., Parker, L.P., Bristow, R.E., Goff, B.A., Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am. J. Obstet. Gynecol. 204 (2011), 466–478.
85. [85] Perri, T., Ben-Baruch, G., Kalfon, S., Beiner, M.E., Helpman, L., Hogen, L.B., Shapira-Frommer, R., Korach, J., Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?. Gynecol. Oncol. 131 (2013), 27–31.
86. [86] Grabowski, J.P., Harter, P., Heitz, F., Pujade-Lauraine, E., Reuss, A., Kristensen, G., Ray-Coquard, I., Heitz, J., Traut, A., Pfisterer, J., du Bois, A., Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol. Oncol. 140 (2016), 457–462.
87. [87] du Bois, A., Rochon, J., Pfisterer, J., Hoskins, W.J., Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecol. Oncol. 112 (2009), 422–436.
88. [88] Petrillo, M., Nero, C., Amadio, G., Gallo, D., Fagotti, A., Scambia, G., Targeting the hallmarks of ovarian cancer: the big picture. Gynecol. Oncol., 2016.